XCXu-Chen Cao

Xu-Chen Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xu-Chen Cao has a total of 225 co-authors. Here are the top co-authors by number of shared publications:

  • Yue Yu

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    25 shared publications
  • Xin Wang

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    23 shared publications
  • Yue Yu

    The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin China

    23 shared publications
  • Xin Wang

    The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin China

    10 shared publications
  • Zheng-Jun Yang

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    9 shared publications
  • Jie Ge

    The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    8 shared publications

Latest Publications

  • Open Access

    Weight‐Adjusted Waist Index and Breast Cancer Prevalence in U.S. Adult Women: A Cross‐Sectional NHANES Analysis (1999–2016)

    by Yili Li, Zhengjun Yang, Yunbo An, Yue Yu, Xuchen Cao, Xin Wang

    Background: Central adiposity, captured by the weight‐adjusted‐waist index (WWI), may correlate with breast cancer risk, but whether the association persists after adjustment for demographic and cardiometabolic confounders remains unclear. We examined the cross‐sectional association between WWI and breast cancer prevalence in U.S. adult women. Methods: Using National Health and Nutrition Examination Survey (NHANES) 1999–2016 data ( n = 6782; 208 breast‐cancer cases), we fit survey‐weighted logistic models with three levels of covariate adjustment, restricted cubic splines (RCS), and Extreme Gradient Boosting (XGBoost)‐based variable importance. Propensity‐score matching (PSM) and sensitivity analyses were performed. Results: After adjustment for age, race, poverty‐to‐income ratio (PIR), hypertension, diabetes, and coronary heart disease (CHD), the highest vs. lowest WWI quartile showed an odds ratio (OR) of 1.84 (95% CI 1.19–2.91; p = 0.008). In Shapley Additive exPlanations (SHAP) analysis of the full analytic cohort ( n = 6782), age dominated variable importance (mean |SHAP| 0.0071), followed by race (0.0016) and WWI (0.0015); this ordering was stable across repeated subsample replicates. RCS showed a significant linear association ( p overall = 0.008), with an exploratory inflection near WWI ≈12.4. Higher WWI was associated with lower estradiol (E2) and sex hormone‐binding globulin (SHBG) and a higher total testosterone (TT)‐to‐SHBG ratio. Conclusions: WWI was cross‐sectionally associated with breast cancer prevalence after adjustment for age, race, PIR, hypertension, diabetes, and CHD, supporting its potential role as a simple marker of central adiposity in descriptive epidemiology.

  • Open Access

    Complications and patient-reported outcomes in breast cancer patients undergoing prepectoral implant-based breast reconstruction: direct-to-implant versus tissue expander-to-implant followed by postmastectomy radiation therapy

    by Wen Kang, Zheng-Jun Yang, Ran Meng, Ao-Xiang Chen, Xue-Jie Zhou, Yue Yu, Xu-Chen Cao

    Background: Optimal implant-based breast reconstruction (IBBR) for patients requiring postmastectomy radiation therapy (PMRT) after prepectoral reconstruction remains unclear. This study compared direct-to-implant (DTI) with tissue expander-to-implant (TEI) reconstruction followed by PMRT, focusing on complications and patient-reported outcomes (PROs). Methods: In this single-center retrospective study, breast cancer patients admitted between December 2018 and December 2024 who underwent prepectoral IBBR followed by PMRT were included. Patients received DTI-PMRT (immediate implant plus PMRT) or TEI-PMRT (immediate expander, PMRT, then exchange). Complications, risk factors, reconstruction failure, and BREAST-Q PROs were compared. Results: Among 217 patients, 146 completed long-term follow-up. TEI-PMRT had higher crude rates of reconstruction failure (14.5% vs 3.7%; p = 0.008), postoperative infection (13.6% vs 3.7%; p = 0.015), and severe capsular contracture (30.2% vs 14.0%; p = 0.030). TEI remained associated with reconstruction failure after adjustment for surgical approach (OR = 3.71, p = 0.011), but attenuated after mesh adjustment (OR = 2.70, p = 0.076). TEI association with severe contracture ( p = 0.030) attenuated after follow-up adjustment (OR = 1.77, p = 0.248). Postoperative infection was strongly associated with reconstruction failure ( p < 0.001). No significant satisfaction difference was detected; sexual well-being improved within TEI-PMRT after exchange (paired t-test, p < 0.001; Wilcoxon signed-rank, p = 0.001). PRO findings were limited by differential attrition and timing differences. Conclusions: In prepectoral IBBR requiring PMRT, TEI-PMRT was associated with higher crude rates of failure and severe contracture than DTI-PMRT, although associations were sensitive to mesh and follow-up adjustment. DTI may be reasonable, but confirmation is required given retrospective design and attrition.

  • Open Access

    Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade

    by Zhengjun Yang, Yuqing Dai, Yinuo Li, Li Xia, Tianrui Li, Xiao Chen, Jiangrui Chi, Yue Yu, Xuejiao Lv, Junjie Li, et al.

    Pathologic complete response (pCR) after neoadjuvant chemotherapy and dual HER2 blockade is associated with improved outcomes in HER2-positive breast cance

  • Open Access

    Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis

    by Yao Wang, Yu Yue, Xu-Chen Cao

    Background: Breast cancer liver metastasis (BCLM) is associated with substantial prognostic heterogeneity and poor survival outcomes. Existing staging systems and prognostic models have a limited capacity for individualized survival prediction for patients with newly diagnosed BCLM, highlighting the need for more accurate and clinically applicable predictive tools. This study aimed to develop a prognostic nomogram for patients with newly diagnosed breast cancer and liver metastases using Surveillance, Epidemiology, and End Results (SEER) database data (2010–2021). Methods: Ten stable prognostic variables—age; tumor size; brain, bone, and lung metastases; histological grade; chemotherapy; estrogen receptor (ER) status; progesterone receptor (PR) status; and human epidermal growth factor receptor-2 (HER2) status—were selected using four machine learning algorithms (Least Absolute Shrinkage And Selection Operator, Extreme Gradient Boosting, Decision Tree, and Random Forest). The SEER cohort was randomly divided into training (70%) and internal validation (30%) cohorts, with an independent external cohort for validation. These variables were incorporated into a multivariate Cox proportional hazards regression model to construct a nomogram. Model performance was evaluated using the concordance index (C-index), calibration curves, decision curve analysis (DCA), and area under the curve (AUC). Results: The C-indices for the training, internal validation, and external validation cohorts were 0.760, 0.740, and 0.787, respectively. The 1-, 3-, and 5-year AUCs were 0.777, 0.757, and 0.764 (training); 0.755, 0.769, and 0.754 (internal validation); and 0.727, 0.752, and 0.801 (external validation), respectively. The calibration curves indicated good agreement and DCA confirmed the clinical utility of the model. Conclusion: The proposed nomogram demonstrated robust predictive performance for patients with breast cancer and liver metastases and may provide valuable prognostic information, pending further validation.

  • Open Access

    IRX1 suppresses breast cancer progression by inhibiting fatty acid de novo synthesis through downregulating ACACA expression

    by Wen-Bo Liu, Lin-Yue Hai, Yuan-Yuan Zhang, Hao-Ran Yue, Xiao-Feng Liu, Bo-Wen Liu, Xin Wang, Xu-Chen Cao, Yue Yu

    Breast cancer remains a major threat to women’s health and survival worldwide. Iroquois homeobox 1 ( IRX1 ), a developmentally regulated transcription factor, acts as a tumor suppressor in several cancers. However, its mechanistic role in breast cancer remains elusive. In this study, we demonstrate that IRX1 is downregulated in breast cancer tissues and cell lines due to promoter hypermethylation. IRX1 functioned as a tumor suppressor both in vitro and in vivo. Mechanistically, IRX1 interacts with NME1 and promotes its nuclear localization. Subsequently, NME1 facilitates the transcriptional regulation of ACACA by IRX1 . The IRX1 - NME1 axis modulates de novo fatty acid synthesis and breast cancer progression by targeting ACACA . In conclusion, our findings reveal that the IRX1- NME1 / ACACA axis plays a critical role in de novo fatty acid synthesis and breast cancer progression, providing new insights into gene regulatory interactions and highlighting its potential as a novel therapeutic target for breast cancer.


  • Open Access

    Multi-omics Data Reveal SLC9A3R2 Promotes Breast Cancer Progression and an Immunosuppressive Microenvironment

    by Zujin Chen, Yao Wang, Guixin Wang, Yue Yu, Xin Wang, Xuchen Cao

    The molecular mechanisms driving the occurrence and progression of breast cancer remain unclear, necessitating the identification of novel molecular biomarkers and therapeutic targets. This study aims to investigate the role of SLC9A3R2 (NHERF2) in breast cancer progression via an integrated multi-scale approach. Analysis of The Cancer Genome Atlas (TCGA) data revealed that SLC9A3R2 is upregulated at both protein and mRNA level in breast cancer tissues, related to advanced tumor stage and poor prognosis, especially in luminal subtypes. Functional enrichment analyses linked high SLC9A3R2 expression to epithelial-mesenchymal transition (EMT), estrogen response, and PI3K-AKT/MAPK signaling pathways. Additionally, SLC9A3R2 expression was negatively correlated with the infiltration level of CD8+ T cell as well as the expression of four main immune checkpoint molecules. Single-cell RNA sequencing analysis of patient samples revealed that SLC9A3R2-positive tumor epithelial cells mediate aberrant cellular communication with endothelial cells, fibroblasts, and macrophages via specific ligand-receptor pairs involving FN1, COL1A1, and COL1A2. Cell functional assays showed that knockdown of SLC9A3R2 significantly impaired the proliferation, migration, and invasion capacities of breast cancer cells. Our findings establish SLC9A3R2 as a key promoter of breast cancer progression, influencing both intrinsic oncogenic pathways and the extrinsic tumor microenvironment (TME), which provides a novel insight for breast cancer treatment.

  • Open Access

    HSPA6 Promotes Ferroptosis in Triple-Negative Breast Cancer by Rewiring Lipid Metabolism to Potentiate Membrane Lipid Peroxidation

    by Lin-Yue Hai, Zhi-Hao Yu, Wen-Bo Liu, Yuan-Yuan Zhang, Yue Xu, Shan Cheng, Hao-Ran Yue, Zhang-Yin Guo, Shi-Jie Yan, Rui Sun, et al.

    Given the lack of effective targeted therapeutic options for triple-negative breast cancer (TNBC), there is an imperative demand for innovative treatment approaches, with ferroptosis standing out as a promising direction. This study identifies HSPA6 as a key ferroptosis sensitizer in TNBC. Mechanistically, HSPA6 binds to NF-κB p65, inhibits its nuclear translocation and Ser468 phosphorylation, thereby suppressing transcription of the lipogenic enzyme FASN and downregulating phospholipid-remodeling enzymes LPCAT1/cPLA2. This dual inhibition enriches membrane phospholipids with polyunsaturated fatty acids, heightening peroxidation susceptibility and triggering ferroptosis. Concurrently, HSPA6-mediated suppression of lipogenesis depletes palmitate, thereby attenuating ANKIB1 palmitoylation and inhibiting its E3 ligase activity. This impairs K48-linked ubiquitination and degradation of HSPA6, forming a stabilizing positive feedback loop. Our study uncovers a HSPA6-p65-FASN-ANKIB1 axis linking lipid metabolism to ferroptosis, offering a novel TNBC therapeutic target.


  • Targeting the SIN1 mediated TTK/LDHA-H3K18la-GLUT3 axis disrupts metabolic-epigenetic crosstalk and suppresses progression in hyperglycolytic breast cancer

    by Zewei Zhao, Wenbin Jia, Zekun Li, Shangheng Shi, Jiaqi Zhou, Chunlan Ning, Zhihao Yu, Xiaofeng Liu, Xuchen Cao, Hong Zheng, et al.